載入中
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
前收盤價
US$52.35
−US$1.65 · -3.06%
盤前
US$52.11
−US$0.24 · -0.46%
10月8日 上午9:28 ET
盤中時間採用ET。市場資料可能有所延遲。
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
日內區間
目前US$52.35
52週區間
目前US$52.35
盤中時間採用ET。市場資料可能有所延遲。
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
日內區間
目前US$52.35
52週區間
目前US$52.35
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 351萬 USD | 3500萬 USD | 3.7億 USD | 43.6萬 USD | 9.13億 USD |
| 銷貨成本 | 2.33億 USD | 1.1億 USD | 1.3億 USD | 1.1億 USD | 1.01億 USD |
| 毛利 | −2.29億 USD | −7525萬 USD | 2.4億 USD | −1.1億 USD | 8.12億 USD |
| 研究與開發 | 2.65億 USD | 3.21億 USD | 3.87億 USD | 4.62億 USD | 3.41億 USD |
| 銷售、一般及管理費用 | 7354.2萬 USD | 7297.7萬 USD | 7616.2萬 USD | 1.02億 USD | 9969萬 USD |
| 營業費用 | 3.39億 USD | 3.91億 USD | 4.62億 USD | 5.63億 USD | 4.38億 USD |
| 折舊和攤銷 | 1947.9萬 USD | 1925.9萬 USD | 1983.7萬 USD | 2417.2萬 USD | 1795.3萬 USD |
| 營業利益 | −5.68億 USD | −4.67億 USD | −2.23億 USD | −6.73億 USD | 3.74億 USD |
| 淨利 | −5.82億 USD | −3.66億 USD | −1.54億 USD | −6.5億 USD | 3.78億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$67.83
上漲空間 29.57%報告持有此股票曝險的交易所交易基金。
ARK Innovation ETFARKK4.7億4.24%55.62億 USD0.75%US$88.30-2.42%
State Street SPDR S&P Biotech ETFXBI1.54億1.49%100.75億 USD0.35%US$150.23-0.44%
iShares Russell 2000 ETFIWM1.27億0.16%785.63億 USD0.19%US$277.7-1.29%
ARK Genomic Revolution ETFARKG1.14億5.38%15.57億 USD0.75%US$50.14-3.11%
Vanguard Extended Market ETFVXF6392.04萬0.07%954億 USD0.05%US$233.49-1.56%
iShares Biotechnology ETFIBB3667.63萬0.35%104.01億 USD0.44%US$203.34+0.12%
Vanguard Russell 2000 ETFVTWO3053.73萬0.17%180億 USD0.06%US$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA2722.04萬0.13%216.99億 USD0.03%US$32.61-1.47%ARK Innovation ETFARKKState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMARK Genomic Revolution ETFARKGVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
